Benefit of Whole-Pelvis Radiation for Patients With Muscle-Invasive Bladder Cancer: An Inverse Probability Treatment Weighted Analysis.


Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333

Informations de publication

Date de publication:
03 Oct 2024
Historique:
medline: 4 10 2024
pubmed: 4 10 2024
entrez: 3 10 2024
Statut: aheadofprint

Résumé

The value of pelvic lymph node irradiation is debated for patients with muscle-invasive bladder cancer (MIBC) undergoing curative-intent radiation therapy (RT). We sought to compare the oncological outcomes between bladder-only (BO)-RT and whole-pelvis (WP)-RT using a large Canadian multicenter collaborative database. The study cohort consisted of 809 patients with MIBC (cT2-4aN0-2M0) who underwent curative RT at academic centers across Canada. Patients were divided into two groups on the basis of the RT volume: WP-RT versus BO-RT. Inverse probability of treatment weighting (IPTW) and absolute standardized differences (ASDs) were used to balance covariates across treatment groups. Regression models were used to assess the effect of the RT volume on the rates of complete response (CR), cancer-specific survival (CSS), and overall survival (OS). After exclusion criteria, 599 patients were included, of whom 369 (61.6%) underwent WP-RT. Patients receiving WP-RT were younger (ASD, 0.41) and more likely to have an Eastern Cooperative Oncology Group performance status of 0-1 (ASD, 0.21), clinical node-positive disease (ASD, 0.40), and lymphovascular invasion (ASD, 0.25). In addition, WP-RT patients were more commonly treated with neoadjuvant chemotherapy (ASD, 0.29) and concurrent chemotherapy (ASD, 0.44). In the IPTW cohort, BO-RT and WP-RT groups were well balanced (all pretreatment parameters with an ASD <0.10). In multivariable analysis, WP-RT was not associated with CR rates post-RT (odds ratio, 1.14 [95 CI, 0.76 to 1.72]; Our study demonstrated that WP radiation was associated with better survival compared with bladder radiation alone after adjusted analysis. Additional randomized controlled trials are needed to confirm our findings.

Identifiants

pubmed: 39361935
doi: 10.1200/JCO.23.02718
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

JCO2302718

Auteurs

Gautier Marcq (G)

Department of Urology, McGill University Health Centre, Montreal, Canada.
Urology Department, Claude Huriez Hospital, CHU Lille, Lille, France.
CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, Lille, France.

Ronald Kool (R)

Department of Urology, McGill University Health Centre, Montreal, Canada.
Department of Abdominal Surgery, Erasto Gaertner Cancer Center, Curitiba, Brazil.

Alice Dragomir (A)

Department of Urology, McGill University Health Centre, Montreal, Canada.

Girish S Kulkarni (GS)

Department of Surgery (Urology), Princess Margaret Cancer Centre and the University Health Network, University of Toronto, Toronto, Canada.

Rodney H Breau (RH)

Division of Urology, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada.

Michael Kim (M)

Department of Surgery (Urology), Princess Margaret Cancer Centre and the University Health Network, University of Toronto, Toronto, Canada.

Ionut Busca (I)

Department of Radiation Oncology, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada.

Hamidreza Abdi (H)

Division of Urology, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada.

Mark Dawidek (M)

Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.

Michael Uy (M)

Division of Urology, McMaster University, Hamilton, Canada.

Gagan Fervaha (G)

Department of Urology, Queen's University, Kingston, Canada.

Nimira Alimohamed (N)

Division of Medical Oncology, University of Calgary, Calgary, Canada.

Jonathan Izawa (J)

Division of Urology, Western University, London, Canada.

Claudio Jeldres (C)

Division of Urology, University of Sherbrooke, Sherbrooke, Canada.

Ricardo Rendon (R)

Department of Urology, Dalhousie University, Halifax, Canada.

Bobby Shayegan (B)

Division of Urology, McMaster University, Hamilton, Canada.

Robert Siemens (R)

Department of Urology, Queen's University, Kingston, Canada.

Peter C Black (PC)

Department of Radiation Oncology, The Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada.

Fabio L Cury (FL)

Department of Urology, McGill University Health Centre, Montreal, Canada.
Department of Radiation Oncology, McGill University Health Centre, Montreal, Canada.

Wassim Kassouf (W)

Department of Urology, McGill University Health Centre, Montreal, Canada.

Classifications MeSH